Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Angelina T Regua und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Grad…. Hauptthemen laut MEDLINE: Janus Kinase 2, Triple Negative Breast Neoplasms, Benzamides, Pyrimidines. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, US Department of Defense.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas Health Sci…
- Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Pathology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health
- US Department of Defense
- American Association for Cancer Research
- METAvivor
Zitieren
APA
Regua, A. T., Bindal, S., Najjar, M. K., Zhuang, C., Khan, M., Arrigo, A. B. J., Gonzalez, A. O., Zhang, X. R., Zhu, J. J., Watabe, K., & Lo, H. W. (2024). Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217023
Vancouver
Regua AT, Bindal S, Najjar MK, Zhuang C, Khan M, Arrigo ABJ, et al. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217023
BibTeX
@article{Regua2024,
author = {Regua, Angelina T and Bindal, Shivani and Najjar, Mariana K and Zhuang, Chuling and Khan, Munazza and Arrigo, Austin B J and Gonzalez, Anneliese O and Zhang, Xinhai R and Zhu, Jay-Jiguang and Watabe, Kounosuke and Lo, Hui-Wen},
title = {Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217023}
}
EUVIMED